-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/fLrHY6eEgV
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/fy7ofd6qjD
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/57bnzhvREP
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/IU4CIepx92
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/PH75l6MAq6
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf
-
-
Mashup Score: 2
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/EPzbQ8lg8o
-
-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/bDkwMIcYIy
-
-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/KZdyZCdY1M
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/rRt7qC3U5G